East Hills, NY (April 11, 2005) - - Pall Corporation (NYSE:PLL) will introduce five new breakthrough technologies at INTERPHEX 2005 aimed at increasing drug manufacturing efficiency through innovation, customization and disposability. The new technologies deliver a combination of benefits that help drug manufacturers enhance throughput and scalability, eliminate time-consuming steps, shorten processing times and reduce labor. By enabling significant time and cost benefits at multiple points within drug production processes, the new products will help meet the needs of the fast-growing, global biopharmaceuticals industry. The biopharmaceuticals market generated revenues of $45 billion in 2004 and is predicted to reach $98.2 billion by 2011.
"The nature of the biopharmaceutical industry requires constant innovation on the part of equipment suppliers to address rapidly changing process needs as new classes of drugs are discovered and developed," says Ken Frank, President of Pall BioPharmaceuticals. "The scope of products we are launching at Interphex reinforce our commitment to providing total fluid management across a wide range of biopharmaceutical applications."
New Product Highlights At a press conference to be held on April 27, Pall will unveil an innovative chromatography technology for super-efficient capture of large molecules used to develop DNA and virus-based drugs. This new technology answers the need for greater throughput and superior binding capacity in a wide range of process chromatography applications.
The Company will also introduce two new additions to its growing portfolio of technologies for disposable processing. It will launch the first customizable Ultrafiltration Skid that incorporates single-use components for downstream processing applications. The new mobile ultrafiltration skid will help manufacturers realize significant time, cost and safety benefits in biopharm production.
The Kleenpak? Connector, a new single-use device, enables aseptic connections to be made instantly, in just a matter of seconds. Validated to withstand autoclave steam temperatures above 121°C, it provides process efficiency for an even broader range of biopharmaceutical applications. It is the only aseptic connection device that does not require laminar flow hoods or other capital equipment to maintain sterility. The disposable device also promotes more efficient manufacturing practices by eliminating the need for cleaning and cleaning validation.
Responding to the growing need for higher performance depth filtration, Pall will also launch the SUPRAdisc? HP depth filter. The new filter enables more efficient cell harvest and clarification steps for drug processing with an expanded range of pharmaceutical grade filtration media. The SUPRAdisc HP filter offers higher dirt holding capacity and longer service life compared to other depth filtration systems.
Also at Interphex 2005, the Company will unveil its next generation software that simplifies operation of complex Tangential Flow Filtration (TFF) systems used in most drug production processes. By allowing engineers to make process changes to TFF systems themselves, the new software avoids time-consuming and costly steps associated with re-programming and re-validation. The software's modular design, user-friendly touch screen and pull-down menus further streamline control of TFF processes.
About Pall Corporation Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicine, semiconductors, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2004 were $1.8 billion. The Company headquarters are in East Hills, New York with extensive operations throughout the world.
Press conference luncheon at Interphex 2005 will be held at 12:00 noon on April 27, room # 4A02. Pall executives are also available for interviews.